Investigation of Pharmacokinetics, Safety, and Tolerability of BAY 63-2521 in Male and Female Subjects With Hepatic Impairment (Classified as Child Pugh A or B) and in Age-, Weight- and Gender-matched Healthy Subjects Following a Single Oral Dose of 1 mg BAY 63-2521 in a Single-center, Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification
Latest Information Update: 04 May 2020
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary arterial hypertension; Pulmonary hypertension
- Focus Pharmacokinetics
- Sponsors Bayer
- 04 May 2020 New trial record